Markets:

Overview

News

Currencies

International

Treasuries

BioXcel Therapeutics, Inc. - Common Stock (NQ:BTAI)

1.950 +0.040 (+2.09%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 24, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioXcel Therapeutics, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

BIOXCEL THERAPEUTICS, INC. (NASDAQ: BTAI) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against BioXcel Therapeutics, Inc.

August 08, 2023

From Bernstein Liebhard LLP

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioXcel, Seagate, Baxter, and Danaher and Encourages Investors to Contact the Firm

August 06, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

August 06, 2023

Via ACCESSWIRE

Analyst Ratings for BioXcel Therapeutics ↗

July 17, 2023

Via Benzinga

Lost Money in BioXcel Therapeutics, Inc? Gibbs Law Group Investigates Potential Securities Law Violations

August 01, 2023

From Gibbs Law Group

Via Business Wire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

August 01, 2023

Via Benzinga

BTAI DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against BioXcel Therapeutics, Inc.

August 01, 2023

From Bernstein Liebhard LLP

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Seagate, Baxter, and BioXcel and Encourages Investors to Contact the Firm

July 31, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

3 Stocks With Sky-High Short Interest Levels

July 31, 2023

BYND, BTAI, and ALLO stand out as high short-interest stocks to watch due to their potential for price fluctuations and short-squeeze opportunities.

Via MarketBeat

BIOXCEL ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against BioXcel Therapeutics, Inc. and Encourages Investors to Contact the Firm

July 27, 2023

From Bragar Eagel & Squire, P.C.

Via Business Wire

BIOXCEL THERAPEUTICS, INC. (NASDAQ: BTAI) SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against BioXcel Therapeutics, Inc.

July 25, 2023

From Bernstein Liebhard LLP

Via GlobeNewswire

ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BTAI

July 24, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

ROSEN, A TOP RANKED LAW FIRM, Encourages BioXcel Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BTAI

July 21, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

July 19, 2023

From The Schall Law Firm

Via Business Wire

BioXcel Therapeutics, Inc. (BTAI) Class Action Notice: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against BioXcel Therapeutics, Inc.

July 18, 2023

From Robbins LLP

Via Business Wire

July 18, 2023

From Bernstein Liebhard LLP

Via GlobeNewswire

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BTAI

July 17, 2023

From The Rosen Law Firm PA

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For July 17, 2023 ↗

July 17, 2023

Via Benzinga

ROSEN, A RESPECTED AND LEADING FIRM, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BTAI

July 16, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BTAI

July 15, 2023

WHY: New York, NY - (NewMediaWire) - July 15, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) between December...

Via NewMediaWire

Topics Lawsuit

Lost Money in BioXcel Therapeutics, Inc? Gibbs Law Group Investigates Potential Securities Law Violations

July 14, 2023

From Gibbs Law Group

Via Business Wire

ROSEN, A LEADING AND RANKED FIRM, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BTAI

July 14, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BTAI

July 13, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

Calling All BioXcel Therapeutics, Inc. (BTAI) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses!

July 13, 2023

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

3 Biotech Stocks to Sell Before They Damage Your Portfolio ↗

July 12, 2023

With the Street generally bearish towards the biotech sector, investors need to identify biotech stocks to avoid at this point.

Via InvestorPlace

Calling All BioXcel Therapeutics, Inc. (BTAI) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses!

July 12, 2023

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioXcel Therapeutics, Inc. (BTAI)

July 11, 2023

From Law Offices of Howard G. Smith

Via Business Wire

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioXcel Therapeutics, Inc. (BTAI)

July 11, 2023

From Glancy Prongay & Murray LLP

Via Business Wire

BTAI CLASS ACTION ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Announces Securities Class Action Lawsuit Filed Against BioXcel Therapeutics, Inc. (BTAI)

July 11, 2023

From Kessler Topaz Meltzer & Check, LLP

Via Business Wire

BIOXCEL THERAPEUTICS, INC. SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against BioXcel Therapeutics, Inc. (NASDAQ: BTAI)

July 11, 2023

From Bernstein Liebhard LLP

Via GlobeNewswire

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

BioXcel Therapeutics, Inc. - Common Stock (NQ:BTAI)

All News about BioXcel Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today